Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335003
| Line item | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|
| Cash flows from investing activities: | ||
| Purchase of investments | (351,045) | (45,084) |
| Maturity and sales of investments | 126,919 | 109,384 |
| Purchase of property and equipment | (2,636) | (75,447) |
| Purchase of intangible assets | (1,000) | (2,000) |
| Acquisition of strategic investment | — | (245,819) |
| Net cash used in investing activities | (227,762) | (258,966) |
| Cash flows from financing activities: |
Item 1. Financial Statements
FAQ
- What is Sarepta Therapeutics, Inc.'s capex?
- Sarepta Therapeutics, Inc. (SRPT) reported capex of $555K in Q2 2026.
- How has Sarepta Therapeutics, Inc.'s capex changed year-over-year?
- Sarepta Therapeutics, Inc.'s capex decreased by 98.3% year-over-year, from $31.8M to $555K.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s capex?
- Over 4 years (2021 to 2025), Sarepta Therapeutics, Inc.'s capex has grown at a 27.6% compound annual growth rate (CAGR), from $38.49M to $101.97M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Sarepta Therapeutics, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude